Ascendis Pharma posts slide presentation on achondroplasia program updates

Reuters2026/08/06 12:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ascendis Pharma published a slide presentation outlining Week 78 Phase 2 COACH data for TransCon CNP plus TransCon hGH in achondroplasia.
Combination therapy showed mean annualized growth velocity of 7.73 cm/year in treatment-naïve children at Week 78, height Z-score change +1.29.
Previously TransCon CNP-treated cohort showed mean annualized growth velocity of 7.67 cm/year at Week 78, height Z-score change +1.10.
Presentation also cited Week 104 pivotal ApproaCH monotherapy data showing durable height, proportionality, lower-limb alignment improvements, tolerability consistent with prior reports.
U.S. YUVIWEL launch update through June 30 showed more than 170 unique enrollments, over 65% cleared for reimbursement; presentation posted at https://investors.ascendispharma.com.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ascendis Pharma posts slide presentation on achondroplasia program updates

You may also like

Crypto prices